Oral Metagenomic Biomarkers in Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic and potentially severe autoimmune disease affecting 2 million in the United States. The role of environmental factors in modulating autoimmunity pathogenesis has been clearly described and yet the specific mechanisms of action remain poorly understood. A growing body of evidence implicates microbiota of mucosal surfaces in the development of autoimmune disorders. Various studies have clearly linked RA to periodontal disease. The latter is linked to the red-complex that includes the oral bacterium Porphyromonas gingivalis. And yet there has not been a systematic analysis of the oral microbiota in RA to determine whether there are specific markers for P. gingivalis (and other oral bacteria) that are linked to RA.

In this study, the investigators will characterize oral microbial composition (microbiome) and gene content (metagenome) of DNA isolated from oral samples obtained from patients with (i) early stage RA prior to biologics treatments and (ii) subsets of RA patients who are responsive or unresponsive to anti-TNF-alpha therapy. The innovative aspect of this study is going beyond the identification of oral bacterial species, to the level of strains and genes that are associated with these groups. The overall hypothesis is that oral microbial variation exists between individuals that influences development of autoimmunity and autoimmune disease.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Procedure: Dental Plaque; Other: Multi-dimensional health assessment questionnaire (MDHAQ); Other: Saliva Collection

Detailed Description

This is a multi-disciplinary research study with five investigators from different, yet complementary, disciplines to establish this new collaboration. There is a high translational potential for information gained from this project based on the collaboration of a rheumatologist, a dentist, oral biologists, and infectious disease experts with expertise in immunology, microbiology, and genomics. In brief, RA participants will be recruited by the rheumatologist. A total of 100 participants will be recruited for two groups to be studied; one group of subjects with RA and the other group will be healthy controls. These two groups will be divided into the following groups for participation in the study: Group 1: will consist of 25 RA adult subjects who have not been treated with biologics which will be compared to 25 healthy controls from age-matched members of the same household. Group 2 will consist of 25 RA adult subjects responsive to first line anti-TNF therapy which will be compared to 25 subjects of the same age and sex with RA who are resistant to two or more TNF antagonists. The participants will be scheduled for a research study visit at the University of Florida Dental Clinic Research Unit. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

The supragingival will be subjected to deep sequencing in the genomics lab. To test two specific aims: 1) testing the hypothesis that oral microbiome profiles based on 16S RNA data are associated with the development of RA or with the response to a specific therapy, and 2) testing the hypothesis that the specific genes, variants, and functional capabilities (metagenome) are associated with RA or with therapeutic response. Upon completion of this pilot study, the investigators will have systematically identified bacterial biomarkers (e.g. species, subspecies, genes) that correlate with RA and may serve as potential targets for disease treatment. These markers may be developed into new drug targets for RA therapy in future studies.

• Study Type: Observational
• Enrollment (Actual): 92

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida College of Dentistry-Periodontics
    • Gainesville, Florida, United States, 32611
      • Randall Malcom VA Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Rheumatoid Arthritis (RA) adult patients who have not been treated with biologics (naïve to biologics), RA patients responsive to first line anti-TNF therapy, RA patients who are resistant to two or more TNF antagonists, and healthy controls from age-matched members of the same household.

Description

Inclusion Criteria:

• with at least 10 natural uncrowned teeth (excluding third molars) must be present.

Exclusion Criteria:

• have less than 10 teeth;
• have been treated with antibiotics within the past 3 months, including patients that require antibiotic prophylaxis prior to dental treatment;
• are immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy);
• participate in another clinical study involving the use of dental products one week prior to the start of the washout period or during the study period; and
• are unwilling or unable to provide informed consent and follow the collection instructions.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
RA - naïve to biologics; This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.	Procedure: Dental Plaque; All participants will have dental plaque removed from different tooth surfaces for supragingival.; Other: Multi-dimensional health assessment questionnaire (MDHAQ); The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.; Other Names: MDHAQ; Other: Saliva Collection; All participants will have a saliva collection.
Healthy Controls; This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.	Procedure: Dental Plaque; All participants will have dental plaque removed from different tooth surfaces for supragingival.; Other: Saliva Collection; All participants will have a saliva collection.
RA responsive to anti-TNF; This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.	Procedure: Dental Plaque; All participants will have dental plaque removed from different tooth surfaces for supragingival.; Other: Multi-dimensional health assessment questionnaire (MDHAQ); The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.; Other Names: MDHAQ; Other: Saliva Collection; All participants will have a saliva collection.
RA non responsive to anti-TNF; This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.	Procedure: Dental Plaque; All participants will have dental plaque removed from different tooth surfaces for supragingival.; Other: Multi-dimensional health assessment questionnaire (MDHAQ); The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.; Other Names: MDHAQ; Other: Saliva Collection; All participants will have a saliva collection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oral microbiome will be catalogued in each group for their association with RA.	A Wilcoxon rank-sum test will be computed on each profile to identify differential metagenomic gene content between each pair of groups (RA patients and controls). The potential microbial functional roles of the KEGG orthologues and eggnog orthologue groups markers in the oral microbiota of RA patients will also be assessed. All results will be corrected for multiple testing using a false discovery rate approach.	Day 1
Metagenomic analyses will be performed to find oral bacteria markers between the groups.	A Wilcoxon rank-sum test will be computed on each profile to identify differential metagenomic gene content between each groups.	18 months

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: United States Department of Defense; VA Medical Center-Gainesville
• Investigators: Principal Investigator: Michael R Bubb, MD, University of Florida; Principal Investigator: Edward K Chan, Ph.D., University of Florida

Study record dates

Study Major Dates

• Study Start: May 1, 2016
• Primary Completion (Actual): August 8, 2019
• Study Completion (Actual): August 8, 2019

Study Registration Dates

• First Submitted: August 31, 2015
• First Submitted That Met QC Criteria: September 4, 2015
• First Posted (Estimate): September 9, 2015

Study Record Updates

• Last Update Posted (Actual): August 12, 2019
• Last Update Submitted That Met QC Criteria: August 8, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Keywords: Rheumatoid arthritis; microbiome; Metagenome
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: IRB201500286; 11712325 (Other Grant/Funding Number: Department of Defense); 12.420 (Other Grant/Funding Number: Department of Defense)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No